Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group

被引：335

作者：

Husain, Aliya N. ^{[1
]}

Colby, Thomas ^{[2
]}

Ordonez, Nelson ^{[3
]}

Krausz, Thomas ^{[1
]}

Attanoos, Richard ^{[4
]}

Beasley, Mary Beth ^{[5
]}

Borczuk, Alain C. ^{[6
]}

Butnor, Kelly ^{[7
]}

Cagle, Philip T. ^{[8
]}

Chirieac, Lucian R. ^{[9
]}

Churg, Andrew ^{[10
]}

Dacic, Sanja ^{[11
]}

Fraire, Armando ^{[12
]}

Galateau-Salle, Francoise ^{[13
]}

Gibbs, Allen ^{[14
]}

Gown, Allen ^{[15
]}

Hammar, Samuel ^{[16
]}

Litzky, Leslie ^{[17
]}

Marchevsky, Alberto M. ^{[18
]}

Nicholson, Andrew G. ^{[19
]}

Roggli, Victor ^{[20
]}

Travis, William D. ^{[21
]}

Wick, Mark ^{[22
]}

机构：

[1] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA

[2] Mayo Clin Arizona, Dept Pathol, Scottsdale, AZ USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[4] Univ Hosp Llandough, Dept Cellular Pathol, Cardiff, S Glam, Wales

[5] Mt Sinai Hosp, Dept Pathol, New York, NY 10029 USA

[6] Columbia Univ, Dept Pathol, Med Ctr, New York, NY USA

[7] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA

[8] Methodist Hosp, Dept Pathol & Genom Med, Houston, TX 77030 USA

[9] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA

[10] Univ British Columbia, Dept Pathol, Vancouver, BC, Canada

[11] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA

[12] Univ Massachusetts, Dept Pathol, Worcester, MA 01605 USA

[13] Anat Pathol Lab, Caen, France

[14] Llandough Hosp, Dept Histopathol, Penarth, S Glam, Wales

[15] PhenoPath Labs, Seattle, WA USA

[16] Diagnost Specialties Lab, Bremerton, WA USA

[17] Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA

[18] Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA 90048 USA

[19] Royal Brompton Hosp, Dept Histopathol, London SW3 6LY, England

[20] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA

[21] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA

[22] Univ Virginia, Dept Pathol, Med Ctr, Charlottesville, VA 22903 USA

来源：

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE | 2013年 / 137卷 / 05期

关键词：

DIFFERENTIATED PAPILLARY MESOTHELIOMA; SARCOMATOID MESOTHELIOMA; LYMPHOHISTIOCYTOID MESOTHELIOMA; IMMUNOHISTOCHEMICAL ANALYSIS; EPITHELIOID MESOTHELIOMA; PERITONEAL MESOTHELIOMA; PROGNOSTIC-SIGNIFICANCE; HOMOZYGOUS DELETION; SYNOVIAL SARCOMA; CELL FEATURES;

D O I：

10.5858/arpa.2012-0214-OA

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Context.-Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. Objective.-To provide updated practical guidelines for the pathologic diagnosis of MM. Data Sources.-Pathologists involved in the International Mesothelioma Interest Group and others with an interest in the field contributed to this update. Reference material includes peer-reviewed publications and textbooks. Conclusions.-There was consensus opinion regarding (1) distinction of benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiation of epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas, and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory. Immunohistochemical panels should contain both positive and negative markers. It is recommended that immunohistochemical markers have either sensitivity or specificity greater than 80% for the lesions in question. Interpretation of positivity generally should take into account the localization of the stain (eg, nuclear versus cytoplasmic) and the percentage of cells staining (>10% is suggested for cytoplasmic membranous markers). These guidelines are meant to be a practical reference for the pathologist.

引用

页码：647 / 667

页数：21

共 103 条

[81] Glycogen-rich mesothelioma [J].